What is the current stock price of Medexus Pharmaceuticals Inc. (MEDXF)?

As of the latest market data, Medexus Pharmaceuticals Inc. (MEDXF) is trading at $2.91. The stock has seen a gain of 2.12% today.

Does Medexus Pharmaceuticals Inc. (MEDXF) pay a dividend?

Based on current data, Medexus Pharmaceuticals Inc. does not have a confirmed active dividend policy.

What is the market cap of Medexus Pharmaceuticals Inc.?

The current market capitalization of Medexus Pharmaceuticals Inc. (MEDXF) is approximately unavailable.

MEDXF

Medexus Pharmaceuticals Inc.·Healthcare

2.91

2.125%(+0.06)

Close Price

2.92

0.413%(+0.01)

Pre-Market

Last Updated: — ET

52W L: $1.6452W H: $2.91

MEDXF NEWS

seekingalpha.com

Feb 12

Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript

newsfilecorp.com

Feb 11

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Management to host conference call at 8:00 AM Eastern time on Thursday, February 12, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2025 (the company's fiscal Q3 2026). All dollar amounts in this press release are in US dollars unless specified otherwise.

newsfilecorp.com

Feb 3

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026.

Company Profile

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2017-11-27

Beta

1.74

Websitewww.medexus.com↗